What did @jackie.schimmel actually say?
Jackie Schimmel, interviewing Kyle Richards, made several pointed claims about GLP-1 medications. Richards said her sister Kathy told her that given her anxiety, she would never try something like Ozempic. Schimmel then listed what she called common side effects: "people are literally losing their hair," losing muscle tone, and in some cases becoming "mixed or paralyzed." She framed these as reasons no one should still be using these drugs. To her credit, she acknowledged she was repeating stories rather than citing data, saying "that's the stories that I'm seeing out there." Richards ended by half-joking that seeing her own body in the mirror makes her more tempted to try it anyway. The conversation sits somewhere between casual gossip and genuine concern, which makes fact-checking it worth doing.
Does the science back this up?
Partially, but the framing is badly distorted. Hair loss and muscle loss are real, documented concerns. Gastroparesis (stomach paralysis) has been reported, though the evidence is more complicated than Schimmel implied.
On hair loss: a condition called telogen effluvium, triggered by rapid caloric restriction and weight loss rather than semaglutide itself, has been reported in clinical trials. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) noted alopecia in roughly 3 percent of participants on semaglutide versus 1 percent on placebo. Real, but not epidemic.
On muscle loss: this is a legitimate concern. A 2023 analysis by Cava and Mittendorfer in Obesity Reviews confirmed that GLP-1 agonists do not selectively preserve lean mass, and without resistance training, users can lose significant muscle alongside fat. This is not a hidden scandal. It is a known clinical consideration that providers are supposed to discuss.
On gastroparesis: a 2023 pharmacovigilance study by Sodhi et al. in JAMA found an increased risk of gastroparesis in GLP-1 users compared to non-users. However, calling people "paralyzed" conflates a serious but manageable GI condition with something far more dramatic.
What did they get wrong (or right)?
The gastroparesis framing is the biggest problem. Calling patients "paralyzed" or "mixed" (likely meaning mixed up or confused) dramatically overstates what the evidence shows. Gastroparesis is a slowing of stomach emptying. It is not paralysis in any neurological sense, and the absolute risk increase from the Sodhi et al. data, while real, is modest.
The hair loss claim is basically accurate but needs context. Hair shedding from rapid weight loss is temporary and well-understood. Framing it as a scary Ozempic side effect without that context misleads people into thinking the drug is doing something uniquely harmful to follicles.
Muscle loss is the claim that deserves the most credit. Schimmel is right that it is a serious concern, and it is genuinely underreported in mainstream GLP-1 coverage. Researchers like Stuart Phillips (McMaster University) have been vocal about the need for protein intake and resistance training during GLP-1 use. Getting this point into a pop-culture conversation is actually useful.
The anxiety concern raised by Kathy Hilton, that someone with anxiety should think twice, has some basis. GLP-1 receptors exist in the brain, and some users report mood changes. But the evidence on whether semaglutide worsens anxiety is not settled.
What should you actually know?
GLP-1 medications are not candy, but they are also not the horror story Schimmel sketches. The risks she named are real but require accurate framing to be useful.
- Hair loss from GLP-1 use is most likely a consequence of caloric restriction, not a direct drug effect. It is typically temporary.
- Muscle loss is a genuine clinical concern. Current guidelines recommend protein targets of at least 1.2 grams per kilogram of body weight and resistance training during GLP-1 therapy.
- Gastroparesis risk is elevated in GLP-1 users, but calling it paralysis is inaccurate and creates unnecessary fear in people who might benefit from treatment.
- Anxiety and GLP-1s: the relationship is being studied, but no regulatory body has flagged semaglutide as contraindicated for anxiety disorders.
- These are prescription drugs. The risks and benefits should be discussed with a licensed provider who knows your full medical history, not evaluated based on podcast anecdotes.